» Factor IX Inhibitor Plasma Weak Control

ROUTINE INHIBITOR NIJMEGEN BETHESDA ASSAYS FIX INHIBITOR NIJMEGEN BETHESDA CONTROLS

Factor IX Inhibitor Plasma Weak Control

Nijmegen Bethesda Controls

Factor IX deficient plasma without Factor IX inhibitor.
This plasma can be used for the control of the determination of Factor IX (FIX) inhibitor according to the Bethesda assays or modified Nijmegen Bethesda assays.

Factor IX Inhibitor Plasma Weak Control is produced from factor IX deficient human plasma to which an inhibitor antibody was added in order to provide a precise neutralizing activity.

Reference	Presentation	Packaging
6-1900-ID	Vial	25 x 0.5 mL

Price list, safety data sheets and notices are accessible to our registered customers.

Treatment for hemophilia B involves injecting the missing Factor IX I.V. to prevent or stop bleeding. A majority of the complications of this treatment are the development of antibodies against FIX, called inhibitors.
The development of an anti-FIX inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by the Bethesda assays or modified Nijmegen Bethesda and is expressed in BU. 1BU neutralizes 50% of the activity of FIX for hemophilia B.

All other coagulation factors have normal values.
The inhibitory capacity is indicated in Bethesda-Nijmegen Units/mL on the certificate of analysis.
Control titrated to the cut-off value according to HAS recommendations.

- 25 cryotubes x 0.5 mL of frozen plasma

CRYOcheck™ Factor VIII Inhibitor Kit
Factor IX Inhibitor Plasma Negative Control
Factor VIII Inhibitor Plasma
Factor VIII Inhibitor Plasma HCV neg
Factor VIII Inhibitor Plasma Negative Control
Factor VIII Inhibitor Plasma Weak Control

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Reactive in liquid form.
	Reactive in lyophilized form.
	Reactive in frozen form.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer
	Distributor.

ROUTINE INHIBITOR NIJMEGEN BETHESDA ASSAYS FIX INHIBITOR NIJMEGEN BETHESDA CONTROLS

Factor IX Inhibitor Plasma Weak Control

Nijmegen Bethesda Controls

Price list, safety data sheets and notices are accessible to our registered customers.

Cryopep Catalogue
Thrombosis Haemostasis 2023

Cryopep Catalogue
Haemostasis Research 2023

Cryopep INHIBITOR NIJMEGEN BETHESDA ASSAYS

Product sheet Factor IX Inhibitor Plasma Weak Control

Miller CH. et al. Haemophilia. 2018

You must identify yourself to search for a certificate of analysis

Factor IX Inhibitor Plasma Weak Control

Nijmegen Bethesda Controls

Product sheet

Price list, safety data sheets and notices are accessible to our registered customers.